IGF1 and Hyperinsulinemia: In people with no chronic diseases, IR could be an earlier stage with sustained compensatory hyperinsulinemia, allowing pro-tumorigenic pathways (high insulin/IGF-1, proliferation, anti-apoptosis, low-grade inflammation, oxidative stress) to act more directly.